DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study

Phase 2positivePGN-EDODM1Positive

AI Analysis

Summary

PepGen's FREEDOM2-DM1 Phase 2 study of PGN-EDODM1 has received DSMB approval to progress to the highest dosage cohort, indicating positive interim safety and tolerability data supporting dose escalation.

Clinical Trial Data

Phase

Phase 2

Outcome Details

DSMB approved dose escalation to highest dosage cohort

Importance:6/10

Sentiment:

0.65

DSMBdose escalationPhase 2FREEDOM2-DM1

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 7, 2026 9:38 AM

Read Original